Redeye comments on Impact Coatings Q4 report which only included minor deviations from our forecasts...
Inga överraskningar i det finansiella Ascelia presenterade under gårdagen sin rapport för det fjärde...
EAB reported H2 comparable operating income of EUR 11.
Redeye retains its positive view on Transtema despite EBITA falling somewhat short of our expectatio...
Redeye recognizes Bambuser's high sequential growth rates in Q4, which align with expectations.
Redeye sees a rather soft Q4 report from BIMobject.
Redeye comments on the announced rights issue in Alzecure.
Redeye gives an additional comment on yesterday’s interim data in Vicore’s phase II IPF study.
Q4 quite in line with expectations Etteplan reported Q4 results quite in line with expectations.
Raute’s Q4 figures didn’t include that many surprises as the company had already disclosed some prel...
Sparekassen Sjælland-Fyn reported profit before loan losses of DKK 105m for Q4 2021, which was a who...
Redeye comments on today’s update on the NEX-18 clinical program.
Den 10 februari 2022 publicerade Aptahem sin delårsrapport för fjärde kvartalet 2021.
Redeye’s expectations were overall in line with Bong’s Q4 numbers.
Etteplan's net sales in Q4 amounted to EUR 85.3m (EUR 82.
Redeye comments on Active Biotech’s year end report for 2021.
Starkt resultat ITAB rapporterade en EBIT på 224 mkr, vilket var i linje med vår prognos (216 mkr).
Redeye comments on Carasent's Q4 report, which was slightly weaker than expected, partly due to issu...
Redeye sees a solid Q4 from Bredband2, with sales and EBIT coming in as we expected.
Redeye provides an initial take on AVTECH’s Q4 figures.
